Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
18 août 2022 09h30 HE | Atossa Therapeutics, Inc.
SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa_Therapeutics_logo-min.png
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers
28 juil. 2022 09h00 HE | Atossa Therapeutics, Inc.
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
20 avr. 2022 09h30 HE | Atossa Therapeutics, Inc.
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
27 janv. 2022 09h30 HE | Atossa Therapeutics, Inc.
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
18 janv. 2022 09h30 HE | Atossa Therapeutics, Inc.
SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
30 sept. 2021 09h30 HE | Atossa Therapeutics, Inc.
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...